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Introduction

1
Radiation therapy has long been a standard treatment for locally advanced carcinoma of the cervix (DiSaia & (Ling, et al., 1987) it has only become routine clinical practice in the 6 past ten to fifteen years (Tanderup, et al., 2010; Pavamani, et al., 2011) . With the advantages of image-based treatment 7 planning, it is possible to calculate the dose at every voxel of the image and delineate soft tissue structures. Therefore,
8
within the limits of uncertainty in structure delineation, dose delivered to organs at risk (OAR) such as the bladder, 9 rectum, uterus, vagina, and paracervical tissues can be determined with precision for each treatment fraction. These 
10
capabilities have been recognized in the standard recommendations for image-based dose recording and a number of Therefore, in order to reduce the overall dose maxima to the bladder and optimize sparing of OAR on at least some 25 fractions, our centre has adopted the practice of varying the amount of bladder filling in consecutive IG-ICBT fractions
26
for cervical cancer patients. In doing so we recognize that the bladder size variation is expected to cause larger 27 discrepancies between the actual cumulative dose and conventional plan-summed DVH parameters than a regimen in 28 which a consistent (e.g. empty) bladder filling is used (Pötter, et al., 2006; Andersen, et al., 2013; Teo, et al., 2015) .
29
An additional limitation of current methods of dose accumulation is that DVH parameters are usually calculated for 30 the whole volume of the hollow OAR, including its fluid contents, whereas only the wall tissue is of radiobiological 31 interest. For these reasons, it is clear that more accurate methods and new dosimetric parameters are needed to replace 32 summed DVH parameters for estimating accumulated dose within the hollow organ walls in situations of repeated 33 fractions with changes in organ shape or size. deformable 'point-set' registration using 'contour' data rather than 'image' data, and iii) study the relationship between 27 the bladder 'toxicity' and its geometrically-localized accumulated dose. The present study aims to meet all the above 28 criteria.
Materials and Methods
30
Patient Materials and Contour Processing
31
The treatment planning data for 60 cervical cancer patients receiving fractionated EBRT plus five HDR CT-based IG-
32
ICBT fractions (using a tandem/ring applicator for most cases and tandem/ovoid for some), were studied 300-550 cGy in one, two or three out of five fractions, usually due to patient-specific factors such as extent and location 38 of the CTV. However, it must be noted that the toxicity assessment in this study was carried out relative to the 39 registered dose data and not the prescribed dose, and thus the actual prescription does not affect this analysis.
40
All patients received 45 Gy in 25 EBRT fractions, prescribed to the ICRU reference point (ICRU Report 62, 1999).
41
The EBRT planning was performed on a single planning CT image set and the patients were not imaged prior to each 42 fraction. However, the patients were instructed to fill their bladder prior to treatment (by drinking 0.5 liter of fluid an 43 hour before treatment and no voiding) and, therefore, roughly the same bladder filling regimen can be assumed for all
44
EBRT treatment fractions. The mean EBRT dose to bladder, based on the initial planning data, was on average 43.6 45 1 in the dosimetric analysis in this study.
2
A Foley-Catheter was used to control bladder filling during HDR planning and delivery. Immediately prior to 3 acquisition of the planning CT, and then again immediately prior to treatment delivery, the bladder was emptied using 4 a syringe connected to the catheter, then another syringe containing the desired volume of fluid was used to fill the 5 bladder. The catheter tube was then secured with a plastic clamp. A water-contrast mixture [ water alone was used for treatment. The aim was to vary the bladder filling volume from fraction to fraction by 8 alternating the amount of fluid injected between 60 cm 3 and 300 cm 3 . In practice, this was not always achievable due
9
to factors such as residual urine in bladder and intolerance of some patients to larger volumes. Also, in some patients,
10
the bladder was purposely kept full to avoid higher doses to small bowel. The fluid volume was recorded for each 11 fraction.
12
For the purposes of this study, the bladder inner and outer surfaces were retrospectively re-contoured by a single 13 observer (RZ) on the planning CT images of all brachytherapy fractions using the MIM Maestro software. This was 14 done to ensure the highest possible accuracy and consistency of contouring (as the contours used for treatment
15
planning had been generated with tight time constraints by various observers), and to obtain both inner and outer 16 bladder wall contours. As a quality assurance indicator, the volume of the bladder-wall tissue was monitored during
17
the contouring process, with the assumption that it should remain reasonably constant for each patient regardless of 18 degree of distension -i.e. distension causes the wall to become thinner, but total wall volume stays constant.
19
The points of attachment of the urethra, as well the two ureters for the cases with CT images of adequate quality,
20
were identified at each scan, and used as anatomical landmarks for accuracy assessment of the deformable registration.
21
These landmarks were well suited for this purpose since they are located in the posterior part of the bladder where the 22 highest dose regions tend to occur. As an additional quality assurance check, a random selection of the bladder-wall
23
contours and landmark points, equivalent to 10% of the cases, were reviewed and approved by a radiologist. For each 24 patient, the bladder inner and outer surfaces and the dose matrix associated with each HDR fraction was imported into
25
MATLAB. The bladder-wall structure was then built by linearly interpolating between neighbouring inner-and outer-
26
surface points so as to form four additional shells in between.
27
CPD Deformable Point-set Registration
28
The detailed description, attributes and optimal parameter settings of the CPD toolbox for registering bladder contour 29 point-sets have been previously published (Zakariaee, et al., 2016) . The same procedure and optimal settings of the 30 registration parameters were used in this study, with one main difference. In this study, the reference point-set was
31
the moving (i.e. deforming) structure, in contrast to the previous procedure, where the reference point-set was the 32 target (i.e. fixed) structure. This was because, in order to locally accumulate (i.e. register) the fraction doses on the 33 contour points of a single (reference) structure, a correspondence must be found for all the points in that point-set.
34
Therefore, CPD was used to register the reference point-set to the other four target point-sets, finding a match for
35
every reference point to another point in each of the target point-sets.
36
The TRE value for each anatomical landmark was calculated, for every registration, as the distance between the 37 matched point in the target point-set and the known position of the corresponding landmark in reference. In order to 38 remove the effect of distension of the chosen reference structure on the scaling of the TRE values, a normalized 39 registration error (NRE) was defined using the equation,
41
where ES is the equivalent sphere of the corresponding volume. the reference point-set were calculated using
9
where rDp is the registered dose at point p and dp,i is the dose at point p in fraction i. The registered doses were also 10 calculated as biologically weighted, 2 Gy fraction equivalents (EQD2), derived using the linear quadratic model (α/β 11 = 3 Gy) (Fowler, 1989 ; Dale & Jones, 1998), 
15
In order to create a 'solid' bladder-wall and accumulate the dose at each 'voxel' of bladder-wall, the reference 
34
Also calculated were the non-contiguous volume of the bladder wall receiving a minimum registered dose of n
35
Gy, rVnGy (evaluated for 3, 5, and 10 Gy), 2 3 parameters for 1and 2 cm 3 (contiguous), and 5 and 10 cm 3
36
(DVH-based) volumes in the EQD2 dosage mask, and the mean and integral dose to the bladder wall. 
10
The descriptive statistics for the dosimetric and volumetric parameters were recorded for the Case and Control
11
groups separately. A two sample t-test analysis was performed at a 5% level of significance for all dose parameters,
12
with the null hypothesis of equal means for the Case and Control groups. In addition, a binomial logistic regression 19 Table 1 . Bladder wall dosimetric and volumetric parameters included in this study.
20
Parameter Definition
3
Minimum registered dose to the contiguous or non-contiguous high dose n-cm 3 volume (n=1-10)
Minimum registered EQD2 dose to contiguous or non-contiguous high dose n-cm 3 volume (n=1-10) rVnGy Non-contiguous volume receiving a minimum registered dose of n Gy (n=3-10)
Mdose
Mean registered dose
Idose
Integral registered dose (∑ , where mi is the mass of each voxel and di is its registered dose)
, where i=fraction number) , where i=fraction number)
The intra-patient variation of the bladder volume (i.e. wall tissue plus lumen) over the five fractions, VolVar, was 2 defined as (maximum-minimum)/minimum of the filling volumes. Also, in order to assess the anatomical movement 3 of the hotspots on the bladder, the location of the hottest point on each fraction was mapped to the reference bladder 4 using the registration outputs. Then, the mean and maximum of all the distances between different pairs of hottest 5 points for the five fractions were calculated. To evaluate the effectiveness of varying the bladder filling in moving the 6 hotspot regions on the bladder and reducing urinary toxicity, a linear regression analysis was performed between (i) 7 the mean and maximum hotspot distances and VolVar, and (ii) urinary toxicity score (on a 0.00-4.00 scale) and VolVar.
8
For both analyses, the p-values for a non-zero slope of the linear regression were calculated.
9
Results
10
The observed bladder LENT-SOMA toxicity scores across all subjects ranged from 0.00 to 3.57 (i.e. Grade 0-4). The 
16
All registrations were visually inspected and found to be reasonable (i.e. no extreme outliers could be identified).
17
For most of the cases, the overall match was quite satisfactory with small apparent discrepancies (see Fig. 2 for an 18 example). Quantitatively, the NREavg values (for the optimal reference fraction, as described previously) ranged from 
25
This confirms the conjecture that simply adding the unregistered dosimetric parameters will not provide an accurate 26 estimate for the magnitude or spatial distribution of the cumulative dose over all fractions.
27
The per-patient, inter-fraction variation of bladder-wall tissue volume was low with an average of (5.4±1.6)% and 28 a maximum of 8%. The average bladder-wall thickness over all fractions of all subjects was found to be 3±1 mm. The 29 range of bladder filling volumes across all fractions and all patients was 71-562 cm 3 . The maximum intra-patient 30 volume variation (maximum volume-minimum volume) ranged between 4.5-427 cm 3 , with a mean of 152±112 cm 3 .
31
The degree of volume variation as measured by VolVar ranged between 3.7% and 353.3% across all cases, with an 32 average of (104±86)%. The slope of the regression line for urinary toxicity score versus VolVar was -0.23 (p=0.03).
33
The ranges of the mean and maximum hotspot separation distances across all cases were 3-38 mm and 5-67 mm,
34
respectively. It must be noted that these separation distances are Euclidean distances and not a geodesic shortest path 
39
The DVH-based (non-contiguous) Table 2 shows the results for a selection of the registered dosimetric and volumetric parameters for the Case and
5
6
Control groups. It can be seen that for all parameters, except one, the mean value for the Case group is higher than the
7
Control group, as expected. V3Gy demonstrated a significant difference between Case and Control means based on two 8 sample t-test at a 5% level of significance (p=0.016). rV5Gy and Idose showed a significant difference at the 10% level.
9
The t-test analysis was also performed for the 3 and 2 3 parameters and the most significant result was 10 observed for 2 10 3 with a p-value of 0.097. 
11
16
Discussion
17
In this study, deformable PSR utility of the CPD toolbox was applied to bladder-wall contour point sets of five 
6
The registration uncertainty achieved in this study (4.8±1.5 mm) is amongst the best reported values for bladder 
12
different sets of data: synthetic data, porcine bladder phantom (using fiducials), and patient data (using bladder neck 13 landmark). While they reported residual distance errors (RDE) of 3.7±2 mm on average, for both porcine bladder and 14 patient data, the amount of variation in bladder size in that study (80-300 cm 3 total volume) was much less than the
15
variations tested in the current study (i.e. 71-562 cm 3 ). Given that it has been shown that the registration error becomes
16
larger with the variation in structure dimensions (Chen, et al., 2016; Wognum, et al., 2014; Zakariaee, et al., 2016 ), a 17 slightly larger registration error is expected in our work.
18
According to the phantom-based PSR validation study (Zakariaee, et al., 2016) , the registration uncertainty for
19
CPD is more tangential than transverse. Therefore, the average NRE error reported in our current clinical study can be 
26
mean parameter values higher in the Cases than in the Controls is 0.002, which is quite significant. However,
27
considering that there are correlations between the parameters, they are not all independent.
28
The correlations between the test parameters and toxicity score were further studied using univariate binomial 29 logistic regression analysis. The outcomes of this analysis also suggested that only rV3Gy might be a predictor for Grade
30
2+ urinary toxicity; however, the effect size in terms of odds ratio was not very large (OR=1.075). If the effect is real,
31
a possible underlying mechanism might be that the urinary endpoints that more effectively influence the average 32 toxicity score (i.e. frequency and urgency for our data set) are more strongly associated with larger volumes of the 33 bladder receiving accumulated doses beyond a certain threshold. Further investigation of this effect would benefit 34 from inclusion of baseline urinary complication data in the analysis in order to account for the effect of higher baseline
35
values that might exist for some patients.
36
In this study, the effectiveness of the practice of varying the bladder filling volume across different HDR BT 
42
The statistical power based on the Case and Control sample sizes for α=0.05 is 0.95 for rV3Gy, which is a strong 43 statistical power considering the accepted standard minimum of 0.80 for avoiding a type II error (i.e. false negative)
44
in rejecting a null hypothesis. However, given the total number of parameters tested, we recognize the chance of 45 multiple comparisons problem in our findings (Miller, 1981) , causing a type I error (i.e. false positive). recognizing that analysis of a larger data set would be required in order to reach more definitive conclusions.
5
Although there was no difference observed in the bladder mean EBRT dose from the planning data between the
6
Case and Control groups, the EBRT dose can play an important role in the observed urinary late effects. Since there 7
was only a single planning image available for each patient and the patients were not imaged prior to each EBRT 8 fraction, the intra-fraction variations could not be accounted for. Therefore, it was not possible to register the EBRT 9 dose across treatment fractions. However, considering that a reasonably consistent bladder filling regimen can be 10 assumed for EBRT treatment fractions, the inter-fraction variations are believed to be small compared to the variations 11 seen for the brachytherapy treatments. That being said, no quality assurance or auditing of the bladder filling during
12
EBRT was performed. A more rigorous study of the dose effect relationship of the urinary late effects would require 13 data with repeated EBRT imaging in order to find the total accumulated dose distributions on the bladder from both 14 EBRT and brachytherapy. Moreover, as mentioned above, baseline urinary complication data is required for a more
15
accurate evaluation of post-treatment toxicity. Such information could potentially lead to a more definitive association
16
between urinary toxicity and registered dose parameters.
17
Conclusion
18
The results of this study show that DVH-summed parameters calculated from unregistered data sets overestimate the 
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